Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Biotechnology
The Future Of Generic Biologics: Should The United States “Follow-On” The European Pathway?, Ingrid Kaldre
The Future Of Generic Biologics: Should The United States “Follow-On” The European Pathway?, Ingrid Kaldre
Duke Law & Technology Review
The United States is embarking on a biotechnology drug revolution. In the last few decades, biotech drugs have saved millions of lives, and the market for these miracle cures continues to grow at an astronomical rate. Unfortunately, as the market for biotech drugs is skyrocketing, drug prices are following suit. As Congress strives to make these new drugs more affordable, it must not ignore significant safety concerns unique to these revolutionary therapies. Congress should follow the lead of the European Union to create an accessible pathway for generic forms of biotech drugs that includes strict regulatory measures to ensure drug …
Mckithen V. Brown: Due Process And Post-Conviction Dna Testing, Elizabeth A. Laughton
Mckithen V. Brown: Due Process And Post-Conviction Dna Testing, Elizabeth A. Laughton
Duke Law & Technology Review
When the Second Circuit decided McKithen v. Brown, it joined an ever-growing list of courts faced with a difficult and pressing issue of both constitutional and criminal law: is there a federal constitutional right of post-conviction access to evidence for DNA testing? This issue, which sits at the intersection of new forensic technologies and fundamental principles of constitutional due process, has divided the courts. The Second Circuit, wary of reaching a hasty conclusion, remanded McKithen’s case to the district court for consideration. The district court for the Eastern District of New York was asked to decide whether a constitutional right …
Regulating Nanotechnology: A Private–Public Insurance Solution, Maksim Rakhlin
Regulating Nanotechnology: A Private–Public Insurance Solution, Maksim Rakhlin
Duke Law & Technology Review
Nanotechnology promises to revolutionize innovation in nearly every industry. However, nanomaterials’ novel properties pose potentially significant health and environmental risks. Views in the current debate over nanotechnology regulation range from halting all research and development to allowing virtually unregulated innovation. One viable regulatory solution balancing commercialization and risk is the adoption of a mandatory private-public insurance program.